SOUTH SAN FRANCISCO, Calif., Jun 07, 2010 (BUSINESS WIRE) --Exelixis, Inc. (NASDAQ: EXEL) announced today that Michael M. Morrissey, PhD, the company's president of research and development, will present at Jefferies 2010 Global Life Sciences Conference at 10:00 a.m. EDT / 7:00 a.m. PDT on Wednesday June 9, 2010 in New York. Mr. Morrissey will discuss the company's corporate strategy, development pipeline, and provide a general business update.

The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.

SOURCE: Exelixis, Inc.

Investor Contacts:
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor Relations
and Corporate Communications
cbutler@exelixis.com
or
DeDe Sheel, 650-837-8231
Associate Director,
Investor Relations
dsheel@exelixis.com